| Rupal Kothari, DO | |
|
325 Central Ave, 2nd Floor, Malvern, PA 19355-3265 | |
| (610) 644-6755 | |
| (610) 647-2063 |
| Full Name | Rupal Kothari |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 27 Years |
| Location | 325 Central Ave, Malvern, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124094073 | NPI | - | NPPES |
| 0019723080002 | Medicaid | PA | |
| 100017249 | Other | PA | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | OS009881-L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Paoli Hospital | Paoli, PA | Hospital |
| Riddle Memorial Hospital | Media, PA | Hospital |
| Bryn Mawr Hospital | Bryn mawr, PA | Hospital |
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Gastroenterology Associates Of Lancaster, Ltd. | 4688575434 | 236 |
News Archive
OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device for orthodontics, has just completed the sale of the product to several key opinion leaders in the United Kingdom.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults, more than two children each and every week are diagnosed with cystic fibrosis (CF). New research at Ryerson University, in partnership with The Hospital for Sick Children, is examining the interaction between lab-tested drugs and the defective protein that causes CF to understand how and why the drugs work and to create stronger, more powerful second generation drugs to treat CF.
Rice University's Andrew Barron and his group, working with labs in Italy, Germany and Greece, have identified specific molecules that could block the means by which the deadly virus spreads by taking away its ability to bind with other proteins.
› Verified 9 days ago
| Entity Name | Regional Gastroenterology Associates Of Lancaster, Ltd. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154422806 PECOS PAC ID: 4688575434 Enrollment ID: O20040115000777 |
News Archive
OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device for orthodontics, has just completed the sale of the product to several key opinion leaders in the United Kingdom.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults, more than two children each and every week are diagnosed with cystic fibrosis (CF). New research at Ryerson University, in partnership with The Hospital for Sick Children, is examining the interaction between lab-tested drugs and the defective protein that causes CF to understand how and why the drugs work and to create stronger, more powerful second generation drugs to treat CF.
Rice University's Andrew Barron and his group, working with labs in Italy, Germany and Greece, have identified specific molecules that could block the means by which the deadly virus spreads by taking away its ability to bind with other proteins.
› Verified 9 days ago
| Entity Name | Main Line Gastroenterology Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467429365 PECOS PAC ID: 9931189784 Enrollment ID: O20040722000304 |
News Archive
OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device for orthodontics, has just completed the sale of the product to several key opinion leaders in the United Kingdom.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults, more than two children each and every week are diagnosed with cystic fibrosis (CF). New research at Ryerson University, in partnership with The Hospital for Sick Children, is examining the interaction between lab-tested drugs and the defective protein that causes CF to understand how and why the drugs work and to create stronger, more powerful second generation drugs to treat CF.
Rice University's Andrew Barron and his group, working with labs in Italy, Germany and Greece, have identified specific molecules that could block the means by which the deadly virus spreads by taking away its ability to bind with other proteins.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rupal Kothari, DO Po Box 350, Sellersville, PA 18960-0350 Ph: (215) 723-2333 | Rupal Kothari, DO 325 Central Ave, 2nd Floor, Malvern, PA 19355-3265 Ph: (610) 644-6755 |
News Archive
OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device for orthodontics, has just completed the sale of the product to several key opinion leaders in the United Kingdom.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.
Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.
Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults, more than two children each and every week are diagnosed with cystic fibrosis (CF). New research at Ryerson University, in partnership with The Hospital for Sick Children, is examining the interaction between lab-tested drugs and the defective protein that causes CF to understand how and why the drugs work and to create stronger, more powerful second generation drugs to treat CF.
Rice University's Andrew Barron and his group, working with labs in Italy, Germany and Greece, have identified specific molecules that could block the means by which the deadly virus spreads by taking away its ability to bind with other proteins.
› Verified 9 days ago
Michael M Mikhail, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 111 Shandon Pl, Malvern, PA 19355 Phone: 610-314-3657 Fax: 610-578-0521 | |
Dr. Ian Steven Udvarhelyi, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2185 Wyndtree Ln, Malvern, PA 19355 Phone: 610-407-7075 Fax: 610-407-4520 | |
Dr. Archana Machavarapu, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 847 Stonecliffe Rd, Malvern, PA 19355 Phone: 404-263-3510 | |
Michael B Wolfson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 325 Central Ave, 2nd Floor, Malvern, PA 19355 Phone: 610-644-6755 Fax: 610-647-2063 | |
Katherine Streitel Borst, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 414 Paoli Pike, Malvern, PA 19355 Phone: 484-596-5254 Fax: 484-596-5404 | |
Maura Macdonald Barr, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 325 Central Ave, Suite 200, Malvern, PA 19355 Phone: 610-644-6755 Fax: 610-647-2063 |